阿替戈利单抗或依马度库金α治疗重症COVID-19肺炎:一项随机2期试验
这项2期、双盲、安慰剂对照研究(COVID-astegolimab-IL)纳入396例住院的重症COVID-19肺炎成人,随机接受静脉阿替戈利单抗、依马度库金α或安慰剂,均联合标准治疗。主要终点为至第28天7分类序贯量表评分达到1或2分的恢复时间。阿替戈利单抗组中位恢复时间11天(HR 1.01,p=0.93),依马度库金α组10天(HR 1.15,p=0.38),安慰剂组10天。关键次要终点(改善恢复、死亡率或预防恶化)未见治疗获益,无新安全信号,不良事件在各治疗组相似,生物标志物显示两药均有药理活性。
要点
- 396例重症COVID-19肺炎住院成人中,阿替戈利单抗组中位恢复11天(HR 1.01,p=0.93),安慰剂组10天。
- 依马度库金α组中位恢复10天(HR 1.15,p=0.38),与安慰剂组10天相比未达统计学显著。
- 关键次要终点(改善恢复、死亡率或预防恶化)均未见治疗获益。
- 无新安全信号,不良事件在各治疗组相似;生物标志物显示两药均有药理活性。
适用人群与场景
- 住院的重症COVID-19肺炎成人。
诊断标准与关键阈值
- 主要终点恢复定义为至第28天7分类序贯量表评分达到1或2分的时间。
处置流程与药物剂量
- 患者随机接受静脉阿替戈利单抗、依马度库金α或安慰剂,均联合标准治疗。
研究设计与关键结果
- 2期、双盲、安慰剂对照研究(COVID-astegolimab-IL),在医院开展,随机396例住院重症COVID-19肺炎成人。
- 阿替戈利单抗组中位恢复时间11天(HR 1.01,p=0.93),依马度库金α组10天(HR 1.15,p=0.38),安慰剂组10天。
- 关键次要终点(改善恢复、死亡率或预防恶化)未见治疗获益。
- 无新安全信号,不良事件在各治疗组相似;生物标志物显示两药均有药理活性。
证据类型、等级与局限
- 证据类型:2期、双盲、安慰剂对照随机试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论:阿替戈利单抗或依马度库金α治疗未改善重症COVID-19肺炎患者的恢复时间。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Severe cases of COVID-19 pneumonia can lead to acute respiratory distress syndrome (ARDS). Release of interleukin (IL)-33, an epithelial-derived alarmin, and IL-33/ST2 pathway activation are linked with ARDS development in other viral infections. IL-22, a cytokine that modulates innate immunity through multiple regenerative and protective mechanisms in lung epithelial cells, is reduced in patients with ARDS. This study aimed to evaluate safety and efficacy of astegolimab, a human immunoglobulin G2 monoclonal antibody that selectively inhibits the IL-33 receptor, ST2, or efmarodocokin alfa, a human IL-22 fusion protein that activates IL-22 signaling, for treatment of severe COVID-19 pneumonia.
DESIGN: Phase 2, double-blind, placebo-controlled study (COVID-astegolimab-IL).
PATIENTS: Hospitalized adults with severe COVID-19 pneumonia.
INTERVENTIONS: Patients were randomized to receive IV astegolimab, efmarodocokin alfa, or placebo, plus standard of care. The primary endpoint was time to recovery, defined as time to a score of 1 or 2 on a 7-category ordinal scale by day 28.
MEASUREMENTS AND MAIN RESULTS: The study randomized 396 patients. Median time to recovery was 11 days (hazard ratio [HR], 1.01 d; p = 0.93) and 10 days (HR, 1.15 d; p = 0.38) for astegolimab and efmarodocokin alfa, respectively, versus 10 days for placebo. Key secondary endpoints (improved recovery, mortality, or prevention of worsening) showed no treatment benefits. No new safety signals were observed and adverse events were similar across treatment arms. Biomarkers demonstrated that both drugs were pharmacologically active.
CONCLUSIONS: Treatment with astegolimab or efmarodocokin alfa did not improve time to recovery in patients with severe COVID-19 pneumonia.
参考来源
- Waters M, McKinnell JA, Kalil AC, et al. Astegolimab or Efmarodocokin Alfa in Patients With Severe COVID-19 Pneumonia: A Randomized, Phase 2 Trial. Crit Care Med. 2022. PMID: 36519984. doi:10.1097/CCM.0000000000005716
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。